From: Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients
A. Variable | Disease specific survival | Overall survival | |||
No.Patients | P | No.Patients | P | ||
(died/total) | (logrank-Test) | (died/total) | (logrank-Test) | ||
Size | T1 | 198/842 | <0.001 | 307/842 | <0.001 |
T2/3 | 414/1082 | 560/1082 | |||
LN | negative | 234/1007 | <0.001 | 386/1007 | <0.001 |
positive | 383/929 | 488/929 | |||
Tumour grade | I | 27/163 | <0.001 | 50/163 | <0.001 |
II | 208/767 | 315/767 | |||
III | 365/947 | 473/947 | |||
Histology | invasive lobular | 48/147 | <0.001 | 69/147 | <0.001 |
invasive ductal | 520/1548 | 727/1548 | |||
special differentiation | 20/148 | 41/148 | |||
lobular and ductal mixed forms | 27/90 | 36/90 | |||
only “invasive tumour” as information | 4/9 | 4/9 | |||
MP | premenopausal | 141/428 | 0.877 | 152/428 | <0.001 |
postmenopausal | 472/1503 | 719/1503 | |||
HER2 | neg | 199/667 | <0.001 | 287/667 | <0.001 |
pos | 61/147 | 73/147 | |||
ER | neg | 183/432 | <0.001 | 213/432 | 0.001 |
pos | 429/1482 | 653/1482 | |||
Chemotherapy | no | 433/1526 | <0.001 | 682/1526 | <0.001 |
yes | 186/416 | 195/416 | |||
Radiation therapy | no | 265/781 | 0.461 | 396/781 | 0.028 |
yes | 354/1161 | 481/1161 | |||
Endocrine therapy | no | 255/733 | 0.820 | 343/733 | 0.024 |
yes | 364/1209 | 534/1209 | |||
NFE2L2 mRNA expression | low (<65th %ile) | 453/1268 | 0.005 | 641/1268 | 0.003 |
high (>65th %ile) | 166/674 | 236/674 | |||
NFE2L2 mRNA expression in ER pos tumours | low (<65th %ile) | 318/968 | 0.013 | 485/968 | 0.004 |
high (>65th %tile) | 111/514 | 168/514 | |||
B. Variable | Relapse-free survival | Overall survival | |||
No.Patients | P | No.Patients | P | ||
(relapsed/total) | (logrank-Test) | (died/total) | (logrank-Test) | ||
Size | T1 | 12/68 | 0.022 | 17/68 | 0.006 |
T2/3/4 | 37/108 | 56/108 | |||
LN | negative | 14/74 | 0.026 | 22/74 | 0.003 |
positive | 33/96 | 47/96 | |||
Tumour grade | I | 3/27 | 0.154 | 15/27 | 0.764 |
II | 34/115 | 42/115 | |||
III | 12/32 | 15/32 | |||
Histology | invasive lobular carcinoma | 5/22 | 0.288 | 5/22 | 0.487 |
invasive ductal carcinoma | 41/135 | 59/135 | |||
ductal carcinoma with specific differentiation | 3/19 | 9/19 | |||
MP | premenopausal | 14/48 | 0.970 | 14/48 | 0.032 |
postmenopausal | 35/128 | 59/128 | |||
HER2 | neg | 36/133 | 0.971 | 51/133 | 0.692 |
pos | 12/40 | 20/40 | |||
ER | neg | 20/49 | 0.061 | 26/49 | 0.831 |
pos | 29/127 | 47/127 | |||
PR | neg | 24/59 | 0.021 | 32/59 | 0.234 |
pos | 25/117 | 41/117 | |||
Chemotherapy | no | 18/90 | 0.022 | 35/90 | 0.382 |
yes | 31/86 | 38/86 | |||
Radiation therapy | no | 14/68 | 0.348 | 33/68 | 0.069 |
yes | 35/107 | 40/107 | |||
Endocrine therapy | no | 18/51 | 0.232 | 30/51 | 0.433 |
yes | 31/125 | 43/125 | |||
NFE2L2 mRNA expression | low (<65th %ile) | 39/114 | 0.013 | 55/114 | 0.081 |
high (>65th %ile) | 10/62 | 18/62 | |||
low (< median) | 36/88 | <0.001 | 48/88 | 0.004 | |
high (> median) | 13/88 | 25/88 | |||
NFE2L2 mRNA expression in ER pos tumours | low (<65th %ile) | 25/82 | 0.005 | 37/82 | 0.034 |
high (>65th %ile) | 4/45 | 10/45 | |||
low (< median) | 23/59 | <0.001 | 32/59 | <0.001 | |
high (> median) | 6/68 | 15/68 |